Corey Boles of Dow Jones Newswires wrote on April 20, 2007 (appearing at SignOnDanDiego.com):
Federal Trade Commission Chairman Deborah Platt Majoras Friday was defiant over the agency's policy of pursuing enforcement action against pharmaceutical companies making payments to generic drug makers to stay out of particular markets.
Speaking at a roundtable discussion at the American Bar Association's Spring Meeting in Washington, Majoras was asked whether the FTC would have to rethink its position on the issue of reverse payments as the practice is called.
She said with “billions of dollars” at stake in the payments being made, the FTC would continue to push for enforcement action in the area. Reverse payments are made by pharmaceutical companies to pursuade generic drug makers from launching their cheap, copycat versions of medicines. That delays consumers' access to cheaper drugs.
Read the full article here.